This study aimed to compare the detection rates of 68 Ga-FAPI-04 PET/CT and 18 F-FDG PET/CT in colorectal cancer. A systematic search of major medical databases was conducted to identify studies up to September 2023. The primary outcome assessed was the detection rate of 68 Ga-FAPI-04 PET/CT and 18 F-FDG PET/CT in the primary tumor. Pooled risk ratios with a 95% CI were calculated using random-effect models to adjust for heterogeneity. Eight studies were included in the meta-analysis. 68 Ga-FAPI-04 PET/CT has higher uptakes in lymph nodes, bone, and peritoneal metastasis compared with 18 F-FDG PET/CT. The detection rate of 68 Ga-FAPI-04 PET/CT based on lesion was better for lymph node metastasis (RR = 0.63, 95% CI 0.47-0.84, P = 0.002) and peritoneal metastasis (RR = 0.52, 95% CI 0.32-0.85, P = 0.009), both imaging modalities had essentially the same diagnostic efficacy in primary tumor (RR = 0.99, 95% CI 0.96-1.02, P = 0.49). 68 Ga-FAPI-04 as a highly promising PET/CT tracer was superior to 18 F-FDG PET/CT in colorectal cancer, especially in detecting lymph node metastases and peritoneal metastases.
Keyphrases
- pet ct
- lymph node
- positron emission tomography
- lymph node metastasis
- systematic review
- loop mediated isothermal amplification
- squamous cell carcinoma
- case control
- real time pcr
- clinical trial
- high resolution
- randomized controlled trial
- sentinel lymph node
- machine learning
- mass spectrometry
- early stage
- meta analyses
- study protocol
- open label
- double blind
- bone regeneration